New TB treatment a ‘game-changer’
A NEW treatment for a drug-resistant strain of tuberculosis can cure 80 percent of sufferers, according to a trial hailed on Monday as a “game changer” in the fight against the global killer.
Doctors in Belarus — a country with one of the highest rates of multidrugresistant tuberculosis in the world — spent months treating patients with a new drug, bedaquiline, alongside other antibiotics.
The results were startling: Of the 181 patients given the new drug, 168 people completed the course and 144 were totally cured.
The World Health Organization says currently only 55 percent of people with multidrug-resistant tuberculosis are successfully treated.
The Belarus trial cure rate — 80 percent — was largely replicated in bedaquiline trials in other countries in eastern Europe, Africa and Southeast Asia, according to abstracts due to be unveiled at a major tuberculosis conference later this week.
“The results from this study confirm ... that newer drugs like bedaquiline can cure and are game changers for people living with multidrug-resistant and extremely drug-resistant tuberculosis,” Paula Fujiwara, scientific director of the International Union Against Tuberculosis and Lung Disease who was not involved in the research, said.
Lead researcher Alena Skrahina of the Republican Research and Practical Center for Pulmonology and TB in Minsk, called the results “promising.”
“Generally, our study confirms the effectiveness of bedaquiline in previous clinical trials, and does not confirm the concerns about safety problems,” she said.
Tuberculosis killed at least 1.7 million people in 2017, according to the WHO, making the airborne infection the world’s deadliest infectious disease.
It kills more than three times as many people as malaria every year and is responsible for the majority of HIV/AIDS deaths.
Despite the huge death toll, tuberculosis receives roughly a tenth of the global research funding that goes to HIV/AIDS. Multidrug-resistant tuberculosis is immune to two of the most common antibacterial drugs used to treat the disease.